Skip to main content
SpringerLink
Log in

Liver metastases

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion Statement

Liver metastases, especially from colorectal primary cancers, are treatable and potentially curable. Imaging techniques such as CT, MRI, and sonography have advanced in recent years and led to increased sensitivity and specificity in the diagnosis of liver metastases.

Liver surgery also has been revolutionized in the past two decades. Dissections along nonanatomic lines have permitted the resection of multiple lesions that previously might have been considered unresectable. We regard resection of a solitary hepatic metastasis or up to four metastases from colorectal carcinoma as the best treatment for this condition.

In patients over 70 years of age and those with medical conditions preventing surgery, we endorse expectant follow-up as long as the tumor remains stable. But if the tumor begins growing rapidly and local techniques cannot be used, we consider systemic chemotherapy. In patients with progressive metastatic liver disease, we initiate systemic therapy or hepatic arterial infusion. In young patients with metastatic disease, even when the disease is indolent or symptomatic, it may be difficult not to treat. We use either local regional therapy (resection or regional infusion) or systemic chemotherapy followed by regional therapy. In patients with neuroendocrine tumors metastatic to the liver, the first approach we use is not to treat because there may be a long period of stable disease. We use Sandostatin (Sandoz Pharmaceuticals, East Hanover, NJ) to treat symptoms. If the tumor progresses and symptoms cannot be controlled, these vascular tumors can be treated by embolization or chemoembolization, with high expectations of response.

Newer approaches to liver metastases such as cryosurgery, chemoembolization, and interstitial radiation are also available. Cryosurgery is an ablative procedure that has not been proven yet to be as effective as surgical removal of metastases. However, in a situation where surgery cannot be performed, cryosurgery is an alternative. Chemoembolism has not been proven to be more effective than systemic therapy for liver metastases, but it allows another regional approach. External localized radiation can be used for patients who fail first-line treatment or in new protocols to delineate its value, perhaps in concert with chemotherapy. We also consider offering external localized radiation in patients who fail first-line treatment, perhaps in concert with chemotherapy. The usefulness of these techniques compared with surgery or regional therapy is being investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pickren JW, Tsukada Y, Lane W: Liver metastases: analysis of autopsy data. In Metastases. Edited by Weiss E, Gilbert H. Boston: GK Medical Publishers; 1982:2.

    Google Scholar 

  2. Kemeny NM, Subarbaker PH, Smith TJ, et al.: A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions. Ann Surg 1982, 195:163–167.

    Article  PubMed  CAS  Google Scholar 

  3. Baron RL, Freeny PC, Moss AA: The liver. In Computed Tomography of the Body with Magnetic Resonance Imaging. Edited by Moss AA, Gamsu G, Genant HK. City?: Publisher?; 1991:735-821.

  4. Castaing D, Emond J, Kunstlinger F, Bismuth H: Utility of operative ultrasound in the surgical management of liver tumors. Ann Surg 1986, 204:600–605.

    Article  PubMed  CAS  Google Scholar 

  5. Vitola J, Delbeke D, Meranze S, et al.: Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996, 78:2039–2042.

    Article  Google Scholar 

  6. Delbeke D, Vitola JV, Sandler M, et al.: Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997, 38:1196–1201.

    PubMed  CAS  Google Scholar 

  7. Moran B, O’Rourke G, Plant G, et al.: Computed tomographic portography in preoperative imaging of hepatic neoplasms. Br J Surg 1995, 82:669–671.

    Article  PubMed  CAS  Google Scholar 

  8. Garbone PP, Bauer M, BandP, et al.: Chemotherapy of disseminated breast cancer; current status and prospects. Cancer 1977, 38:2916–2922.

    Article  Google Scholar 

  9. Kemeny N, Lokich JJ, Anderson N, Ahlgren JD: Recent advances in the treatment of advanced colorectal cancer. Cancer 1993, 71.

  10. Kemeny N, Yagoda A, Braun D, et al.: Therapy for metastatic colorectal carcinoma with combination of methyl-CCNU, 5-fluorouracil, vincristine and streptozotocin (MOF-Strep). Cancer 1980, 45:876–881.

    Article  PubMed  CAS  Google Scholar 

  11. Conti JA, Kemeny N, Saltz LB, et al.: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:709–715.

    PubMed  CAS  Google Scholar 

  12. Rougier P, Bugat R, Donillard JY, et al.: Phase II study of irinotecan treatment of advanced colorectal cancer in chemotherapynaive patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15:251–260.

    PubMed  CAS  Google Scholar 

  13. Pitat HC, Wender DB, O’Connell MJ, et al.: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997, 15:2910–2919.

    Google Scholar 

  14. Machover B, Diaz Rubio E, de Gramont A, et al.: Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7:95–98.

    PubMed  CAS  Google Scholar 

  15. Becouarn Y, Ychou M, Mucruex M, et al.: Oxaliplatin (LOHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients; preliminary activity/toxicity report [abstract]. Proc Am Soc Clin Oncol 1997, 16:229a.

    Google Scholar 

  16. Giaccheti S, Zidani R, Perpoint B, et al.: Phase III trial of l5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) [abstract]. Proc Am Soc Clin Oncol 1997, 16:229a.

    Google Scholar 

  17. Saltz LB, Leichman CG, Young CW, et al.: A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995, 75:782–785.

    Article  PubMed  CAS  Google Scholar 

  18. Van Hoff DD, Rothenberg ML, Pitot HC, et al.: Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer: overall results of FDA-reviewed pivotal US clinical trials [abstract]. Proc Am Soc Clin Oncol 1997, 16:22a.

    Google Scholar 

  19. Giacchetti S, Zidani R, Perpoint B, et al.: Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) [abstract]. Proc Am Soc Clin Oncol 1997,16:29a.

    Google Scholar 

  20. Extra JM, Espie M, Calvo J, et al.: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990, 25:299–303.

    Article  PubMed  CAS  Google Scholar 

  21. Gonzales-Baron M, Felia J, de la Gandara J, et al.: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A Phase II study. Eur J Cancer 1995, 31:2225–2219.

    Google Scholar 

  22. Ensminger WD, Rosowsky A, Raso V: A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 1978, 38:3789–3792.

    Google Scholar 

  23. Scheele J, Stangl R, Altendorf-Hofmann A, et al.: Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991,110:13–29.

    PubMed  CAS  Google Scholar 

  24. Doci R, Gennari L, Bignami P, et al.: One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991, 78:797–801.

    Article  PubMed  CAS  Google Scholar 

  25. Elias D, Laser P, Roughier P, et al.: Nouvel echec dans la tentative de definition des indications d’exerese des metastases hepatiques d’origine colo-rectales. De/CI/Nouveche; 1991.

  26. Rosen CB, Nagorney D, Taswell H, et al.: Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992, 216:493–505.

    Article  PubMed  CAS  Google Scholar 

  27. Cady B, McDermott WWJ: Major hepatic resection for metachronous metastases from colon cancer. Ann Surg 1985, 201:204–209.

    Article  PubMed  CAS  Google Scholar 

  28. Cady B, Stone MD, McDermott WV Jr, et al.: Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg 1992,127:561–569.

    PubMed  CAS  Google Scholar 

  29. Rubinsky B, Lee CY, Bastacky J, et al.: The process of freezing and the mechanism of damage during hepatic cryosurgery. Cryobiology 1990, 27:85–97.

    Article  PubMed  CAS  Google Scholar 

  30. Zhou XD, Yu YQ, et al.: The role of cryosurgery in the treatment of hepatic cancer. J Cancer Res Clin Oncol 1993, 120:100–102.

    Article  PubMed  CAS  Google Scholar 

  31. Weaver ML, Atkinson D, Zemel R: Hepatic cryotherapy in treating colorectal metastases. Cancer 76:210–214.

  32. Ravikumar TS, Steele GJ, Kane R et al.: Experimental and clinical observations on hepatic cryosurgery for colorectal metastases. Cancer Res 1991, 51:6233–6237.

    Google Scholar 

  33. McCarthy TM, Kuhn JA: Cryotherapy for liver tumors. Oncology 1998, 12:979–987.

    Google Scholar 

  34. Carrasco CH, Charnsangarej C, Ajani J, et al.: The carcinoid syndrome: palliation by hepatic artery embolization. AJR 1986, 147:149–154.

    PubMed  CAS  Google Scholar 

  35. Ajani J, Carrasco CH, Charnsangavej C, et al.: Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 108:340–344.

  36. Robertson JM, Lawrence TS, Walker S, et al.: The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int J Radiat Oncol Biol Phys 1995, 32:445–450.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Room H916,1275 York Avenue, 10021, New York, NY

    Nancy E. Kemeny MD & Ilan G. Ron MD

Authors
  1. Nancy E. Kemeny MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilan G. Ron MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kemeny, N.E., Ron, I.G. Liver metastases. Curr Treat Options Gastro 2, 49–57 (1999). https://doi.org/10.1007/s11938-999-0018-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-999-0018-1

Keywords

Search

Navigation